BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 15821484)

  • 1. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.
    Liu Z; Guo BL; Gehrs BC; Nan L; Lopez RD
    J Urol; 2005 May; 173(5):1552-6. PubMed ID: 15821484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.
    Guo BL; Liu Z; Aldrich WA; Lopez RD
    Breast Cancer Res Treat; 2005 Sep; 93(2):169-75. PubMed ID: 16187237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
    Liu Z; Guo B; Lopez RD
    J Gastroenterol Hepatol; 2009 May; 24(5):900-11. PubMed ID: 19175829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies.
    Lopez RD; Xu S; Guo B; Negrin RS; Waller EK
    Blood; 2000 Dec; 96(12):3827-37. PubMed ID: 11090067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
    Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
    J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
    Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
    Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic β-Adrenergic Receptor Activation Augments the
    Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
    Front Immunol; 2019; 10():3082. PubMed ID: 32038628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
    Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
    J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.
    Alexander AA; Maniar A; Cummings JS; Hebbeler AM; Schulze DH; Gastman BR; Pauza CD; Strome SE; Chapoval AI
    Clin Cancer Res; 2008 Jul; 14(13):4232-40. PubMed ID: 18594005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
    Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
    Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
    Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells.
    Tomogane M; Sano Y; Shimizu D; Shimizu T; Miyashita M; Toda Y; Hosogi S; Tanaka Y; Kimura S; Ashihara E
    Biochem Biophys Res Commun; 2021 Oct; 573():132-139. PubMed ID: 34407491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
    Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
    Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tim-3 suppresses the killing effect of Vγ9Vδ2 T cells on colon cancer cells by reducing perforin and granzyme B expression.
    Li X; Lu H; Gu Y; Zhang X; Zhang G; Shi T; Chen W
    Exp Cell Res; 2020 Jan; 386(1):111719. PubMed ID: 31726050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of human peripheral blood γδ T cells using zoledronate.
    Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
    Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
    PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
    Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
    J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens.
    Holmen Olofsson G; Idorn M; Carnaz Simões AM; Aehnlich P; Skadborg SK; Noessner E; Debets R; Moser B; Met Ö; Thor Straten P
    Front Immunol; 2021; 12():645131. PubMed ID: 34149689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.